annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
8:00 AM - 9:30 AM
CLINICAL SCIENCE SYMPOSIUM
The MEK Pathway
Location: E354a
CME credit: 1.5
Track(s): Developmental Therapeutics
Alex A. Adjei, MD, PhD—Chair
Roswell Park Cancer Institute
Discussion
8:00 AM David B. Solit, MD
Memorial Sloan-Kettering Cancer Center
Introduction
8:15 AM Safety and efficacy results from the first-in-human study of the oral MEK 1/2
inhibitor GSK1120212. (Abstract #2503)
J. R. Infante, L. A. Fecher, S. Nallapareddy, M. S. Gordon, K. T. Flaherty,
D. S. Cox, D. J. DeMarini, S. R. Morris, H. A. Burris, W. A. Messersmith
8:30 AM First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic
(PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in
patients (pts) with advanced solid tumors. (Abstract #2504)
J. Delord, N. Houede, A. Awada, A. Taamma, S. J. Faivre, T. Besse-Hammer,
A. Italiano, C. Vignaud, M. Donica, E. Raymond
8:45 AM Phase I dose-escalation study of E6201, a MEK-1 inhibitor, in advanced solid
tumors. (Abstract #2505)
M. J. Borad, C. E. Akerele, R. K. Ramanathan, D. W. Northfelt, L. Reyderman,
D. Verbel, K. Feit, D. D. Von Hoff, R. Tibes
Discussion
9:00 AM Patricia LoRusso, DO (Abstracts #2503–2505)
Karmanos Cancer Institute
Closing
196